Most Read Articles
Roshini Claire Anthony, 27 Jun 2019

A 2-week course of the immunotherapy drug teplizumab delayed the onset of type 1 diabetes (T1D) in individuals at high risk for the condition, according to a phase II trial conducted by the TrialNet Study Group and presented at ADA 2019.

Vaccination not linked to subdural haematomas in babies

04 Jun 2019
The China-branch of the WHO has been urging China’s State Council to expand its childhood immunisation programme to include flu vaccines as part of the core vaccines that are provided at free of charge.

There appears to be no temporal link between vaccination and the development of subdural haematomas in infants, a recent study has found.

Researchers performed a prospective, population-based study on 228 infants who had received a vaccine shot. Computerized tomography scan or magnetic resonance imaging was performed to detect the presence of subdural haematoma. Cases were matched with controls based on chronological and gestational age.

Of the participants, 28 were positive for subdural haematomas: 22 had abusive while six had nonabusive head trauma. The remaining 200 children were designated as controls, of whom 61 percent (n=121) had available vaccination information. Majority of those with available vaccine data had received a hexavalent (n=124) pneumococcal (n=123) vaccine; 15 had not received any shots.

After matching, the analysis was carried out in 28 infants with subdural haematomas and in 62 controls without the condition. Cases and controls were not significantly different in terms of the frequency of receiving at least one vaccination since birth (86 percent vs 89 percent; odds ratio [OR], 0.77, 95 percent CI, 0.17–3.86; p>0.50).

The same was true for the frequency of vaccination within the last 7 (11 percent vs 11 percent; OR, 0.94, 0.08–6.96), 14 (18 percent vs 22 percent; OR, 0.70, 0.12–2.92) and 21 (18 percent vs 27 percent; OR, 0.48, 0.08–1.98) days before imaging. Median time since last vaccination (1.4 vs 1.3 months; p=0.62) was comparable in both groups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 27 Jun 2019

A 2-week course of the immunotherapy drug teplizumab delayed the onset of type 1 diabetes (T1D) in individuals at high risk for the condition, according to a phase II trial conducted by the TrialNet Study Group and presented at ADA 2019.